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Abstract  
Genome Wide Association Studies (GWAS) revealed SNP rs889312 on 5q11.2 to be 
associated with breast cancer risk in women of European ancestry. In an attempt to 
identify the biologically relevant variants, we analysed 909 genetic variants across 
the 5q11.2 locus in 103,991 breast cancer cases and controls from 52 studies in the 
Breast Cancer Association Consortium. Multiple logistic regression analyses 
identified three independent risk signals: The strongest associations are with 15 
correlated variants (iCHAV1) where the minor allele of best candidate, rs62355902,  
associates with significantly increased risks of both estrogen receptor-positive (ER+: 
OR=1.24, 95% CI 1.21-1.27; P-trend=5.7×10-44) and estrogen receptor-negative 
tumors (ER-: OR=1.10, 95% CI 1.05-1.15; P-trend=3.0×10-4). After adjustment for 
rs62355902, we found evidence for the association of a further 173 variants 
(iCHAV2) containing three subsets with a range of effects, of which the strongest is 
SNP rs113317823 (P-cond=1.61×10-5); and five variants comprising iCHAV3 (lead 
rs11949391; ER+: OR=0.90, 95% CI 0.87-0.93; P-cond=1.4x10-4). Twenty six 
percent of the prioritized candidate variants coincide with four putative regulatory 
elements that interact with the MAP3K1 promoter through chromatin looping and 
affect MAP3K1 promoter activity. Functional analysis indicates the cancer risk alleles 
of four candidates increase MAP3K1 transcriptional activity: rs74345699 and 
rs62355900 (iCHAV1); rs16886397 (iCHAV2a); and rs17432750 (iCHAV3). 
Chromatin immunoprecipitation analysis revealed diminished GATA3 binding to the 
minor (cancer protective) allele of rs17432750, indicating a mechanism for its action. 
We propose that the cancer risk alleles act to increase MAP3K1 expression in vivo 
and may promote breast cancer cell survival. 
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Introduction 
One of the first Genome Wide Association Studies (GWAS) for breast cancer [MIM 
114480] susceptibility identified a SNP at 5q11.2, rs889312, associated with risk of 
breast cancer in women of European ancestry.1 In the most recent analyses by the 
Breast Cancer Association Consortium (BCAC), the minor allele of rs889312 was 
associated with a per-allele Odds Ratio (OR)=1.12 (95% Confidence Intervals (CI) 
1.10-1.15; P-trend=1.8×10-26).2 The association was stronger for ER-positive disease 
(OR=1.14, 95% CI 1.11-1.17; P=1.1x10-26 in the most recent BCAC analysis) but 
also seen for ER-negative (OR=1.06, 95% CI 1.03-1.10; P=0.0024) and triple 
negative disease (OR=1.11, 95% CI 1.02-1.20; P=0.016).3 SNP rs889312 was also 
reported to be associated with an increased breast cancer risk in BRCA2 [MIM 
600185] mutation carriers.4  
 
The GWAS SNP, rs889312, lies approximately 80kb centromeric of MAP3K1 [MIM 
600982], the gene encoding Mitogen-Activated Protein Kinase Kinase Kinase1, also 
known as MEK kinase 1 (MEKK1) – a stress-induced serine/threonine kinase with 
apparent dual functions: MEKK1 induces cell proliferation through a 
RAS/RAF/MEK/ERK signaling pathway5 but, upon caspase cleavage, generates a 
fragment which has a pro-apoptotic function.6,7 Furthermore, MEKK1 regulates 
transcription of key cancer related genes such as MYC8 [MIM 190080], TP539 [MIM 
191170] and JUN10 [MIM 165160] through its signal transduction pathway.  There is 
already evidence of a role for MAP3K1 in breast cancer pathogenesis: MAP3K1 
driver mutations have been observed in luminal A and B type breast tumors11 and 
MAP3K1 expression has been associated with specific breast tumor subtypes.12 
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In this study, we have performed genetic epidemiological analyses on all common 
variants at 5q11.2, together with in silico and in vitro analyses of candidate causal 
variants, and identified strong candidates that we propose are functionally related to 
breast cancer risk. Specifically, we provide evidence that these associations are 
mediated through MAP3K1. 
 
Materials and Methods 
SNP selection and genotyping 
We identified all SNPs from a 305kb interval on 5q11.2 (GRCh37 positions 
55,983,657–56,288,810) with a minor allele frequency (MAF) >0.02 in Europeans 
using the March 2010 release of the 1000 Genomes Project.13 SNPs with an Illumina 
designability score of >0.8, and r2>0.1 with rs889312, together with a tagging set 
(r2>0.9) for all other known SNPs in the interval, were selected for inclusion on the 
iCOGS custom array.2 In total, 352 SNPs were selected, of which 300 passed post-
genotyping quality control criteria.2 To improve SNP coverage across the locus, 16 
further SNPs, selected from the October 2010 release of the 1000 Genomes Project 
were genotyped in a subset of two BCAC studies (SEARCH and the combined 
Copenhagen studies CPGS and CCHS) using a Fluidigm array according to the 
manufacturer’s instructions. These two datasets were used to impute all genotypes 
of other common variants in this interval, using IMPUTE2 and the January 2012 
1000 Genomes Project release as reference.14 All participants provided written 
informed consent. Study characteristics and iCOGS methodology have been 
previously reported.2  
 
Statistical analyses 
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Associations with breast cancer risk in BCAC were evaluated by comparing SNP 
genotype frequencies in cases and controls using unconditional logistic regression. 
Analyses were adjusted by study and seven principal components.2 The primary 
analysis fitted each SNP as an allelic dose and tested for association using a 1-
degree-of-freedom trend test (P-trend) with associated odds ratio (OR) and 95% 
Confidence Intervals (95% CI). To identify independent risk signals, stepwise 
conditional analysis was performed in R with the function "step", including any 
variant with P-value<10-4 in the single SNP analysis to calculate the most 
parsimonious model using a penalty value of k=10. The null model included study 
and principal components. Haplotype analysis was performed in R using the 
package "haplo.stats", and the analyses adjusted for study and principal 
components. 
 
Cell lines 
The normal breast epithelial cell line Bre-80 was cultured as described previously.15 
The breast cancer cell lines MCF7, T-47D and MDA-MB231 were cultured in 
RPMI1640 medium supplemented with 10% fetal calf serum, antibiotics, sodium 
pyruvate and, in the case of MCF7 and T-47D cells, 10 g/ml insulin. 
 
Chromatin conformation capture (3C) 
3C libraries were generated with EcoRI from the cell lines above as described 
previously.16 3C interactions were quantitated by real-time PCR (qPCR) with primers 
designed within the EcoRI restriction fragments spanning the 5q11.2 risk locus 
(Table S1). qPCR was performed as described previously17 using at least two 
independent 3C libraries from each cell line with each experiment quantified in 
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duplicate. Two BAC clones (RP11-378G4 and RP11-1146C6) covering the 5q11.2 
region were used to create an artificial library of ligation products in order to 
normalize for PCR efficiency. As an internal control, interaction frequencies were 
normalized to that of the EcoRI fragment immediately upstream of the promoter/bait 
fragment. 
 
Plasmid construction  
A MAP3K1 promoter-driven luciferase reporter construct was generated by inserting 
a 1928 bp fragment containing the MAP3K1 promoter and the transcription start site 
(GRch37 chr5:56109070-56110997) into the MluI and HindIII sites of pGL3-Basic. To 
assist cloning, AgeI and SbfI sites were inserted into the BamHI and SalI sites 
downstream of the luciferase gene. A 1575 bp PRE-A fragment, a 1765 bp PRE-B2 
fragment, a 2357 bp PRE-B3 fragment, a 2203 bp PRE-C fragment and a 1519 bp 
PRE-D fragment were PCR generated using primers designed with AgeI and SbfI 
sites and cloned into the modified pGL3-MAP3K1 promoter construct. PRE-B was 
too large (~7 kb) to be cloned in its entirety so three subregions containing iCHAV1 
(PRE-B1), iCHAV2b (PRE-B2) and iCHAV3 (PRE-B3) variants were cloned 
separately. The minor alleles of individual SNPs were introduced into promoter and 
PRE sequences, containing the major alleles of any other causal candidate variants, 
by overlap extension PCR. All constructs were sequenced to confirm variant 
incorporation (AGRF, Brisbane, Australia). PCR primers are listed in Table S2. For 
the PRE-B1 construct, a 2129 bp region spanning chr5:56028968-56031097 
(GRCh37) was synthesized with AgeI and SbfI sites incorporated at the 5’ and 3’ 
ends (GenScript, Piscataway, NJ, USA) to assist cloning into the MAP3K1 promoter 
construct. The cloned regions are highlighted in Figure 2B. 
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Reporter assays and estrogen induction 
Bre-80 and MCF7 cells were transfected with equimolar amounts of luciferase 
reporter plasmids and 50 ng of pRLTK transfection control plasmid with 
Lipofectamine 2000. The total amount of transfected DNA was kept constant at 600 
ng for each construct by adding pUC19 as a carrier plasmid. Luciferase activity was 
measured 24 h post-transfection by the Dual-Glo Luciferase Assay System. To 
correct for differences in transfection efficiency or cell lysate preparation, Firefly 
luciferase activity was normalized to Renilla luciferase. For the assays under basal 
conditions, the activity of each construct was calculated relative to the construct 
containing the MAP3K1 promoter alone, the activity of which was defined as 1. 
 
For estrogen induction assays, we treated cells as described.18 Briefly, 24 h after 
plating MCF7 cells into wells, medium was replaced with that containing 10 nM 
fulvestrant for 48 h, which was used to inhibit estrogen induced gene expression, 
thereby creating a baseline of expression for reporter assays. Cells were then 
incubated with fresh medium containing either 10 nM estrogen (17-estradiol) or 
DMSO (as vehicle control) and transfected with reporter plasmids. Luciferase assays 
were performed as above after 24 h. Statistical significance was tested by repeated-
measures ANOVA, using the Greenhouse-Geisser correction for non-sphericity, 
followed by Dunnett’s multiple comparisons test in GraphPad Prism. 
 
ChIP assays 
Chromatin immunoprecipitation (ChIP) assays were carried out as previously 
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described.19 GATA3 specific mouse monoclonal antibodies were obtained from 
Santa Cruz Biotech (sc268). Precipitate and input were used in qPCR using SYBR 
green master mix as described.19 Primer sequences are listed in Table S3. Both 
rs17432750 primer sets gave identical enrichment and the identity of the larger 
fragment was confirmed by Sanger sequencing. All values obtained were normalized 
to input and enrichment is given relative to the negative CCND1 [MIM 168461] 
control. Allele-specific ChIP was carried out by using a TaqMan SNP genotyping 
assay (Applied Biosystems) on the ChIP material. In the TaqMan assay two different 
fluorophores are each linked to a probe detecting the two different alleles. 
Amplification of each allele was followed using an Applied Biosystems Real Time 
PCR machine (7900HT) and the data analysed using the SDS software. The SDS 
software converts the raw data to fluorescence intensity for each allele and then 
plots the results as a scatter graph of allele X versus allele Y. We tested the 
accuracy of this assay by genotyping known mixtures of homozygous ZR751 and 
T47D (C/C), and MDA-MB0-468 (A/A) cell line DNA (Figure S1). For the allelic 
discrimination three independent experiments were carried out and gave similar 
results - a representative example is shown.  
 
GATA3 siRNA knockdown for reporter assay 
GATA3 (MIM 131320; L-003781-00) and non-targeting (D-001810-10-20) ON-
TARGETplus SMARTpool siRNAs for were purchased from Thermo Scientific. For 
knockdown, Bre-80 cells were co-transfected with the relevant luciferase reporter 
plasmids and 100 nM of either GATA3 or non-targeting siRNAs with Lipofectamine 
2000. Luciferase assays were performed as described above after 24 h. To validate 
GATA3 knockdown, qPCR was performed as described previously (Figure S9).17 
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Expression quantitative trait locus (eQTL) analysis 
eQTL analysis was undertaken in two sample sets of adjacent normal breast 
samples from women of European decent: the first set contained 135 samples 
collected for the METABRIC study20; the second set was extracted from the TCGA 
breast cancer study21 data and contained 56 samples.  Matched gene expression 
(Illumina HT-12 v3 microarray for the METABRIC data; Agilent G4502A-07-3 
microarray for the TCGA data) and germline SNP data that was either genotyped 
(Affymetrix SNP 6.0) or imputed (1,000 Genomes Project, March 2012 data using 
IMPUTE version 2.0) were used. Correlations between all imputed and genotyped 
variants at the 5q11.2 locus and expression levels of eight (METABRIC) or four 
(TCGA) genes present in the fine-mapped region were assessed using a linear 
regression model in which an additive effect on expression level was assumed for 
each copy of the rare allele. Calculations on the METABRIC data were carried out 
using the eMap library in R, and on the TCGA data using the SNPTEST software. 22 
 
Results 
Genotyping of case-control studies 
Three hundred SNPs at the 5q11.2 locus (GRch37 positions 55,983,657–
56,288,810) were successfully genotyped using the iCOGs chip, in 103,991 breast 
cancer cases and controls from 52 BCAC studies, of which 41 (46,451 cases and 
42,599 controls) were of European, nine were of Asian (6,269 cases and 6,624 
controls) and two were of African-American ancestry (1,116 cases and 932 controls). 
Using these data, together with data on a further 16 SNPs, genotyped in two BCAC 
studies (SEARCH and the combined Copenhagen studies CPGS and CCHS), we 
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imputed genotypes for 909 variants with MAF>0.02 (out of a possible 911) and 
imputation r2>0.3, using the January 2012 release of the 1000 Genomes Project as 
reference.  
 
Potential breast cancer risk signals in European studies 
Figure 1A shows the Manhattan plot of the 909 genotyped and imputed SNPs 
(r2>0.3) for overall breast cancer risk in European studies. Genotype and association 
results for all 909 SNPs are presented in Table S4. Five hundred and forty one 
variants display association with overall breast cancer risk at P-trend<10-4 (Table 
S5). All associations are consistent with a log-additive model. 
 
In a forward stepwise conditional analysis, using the SNPs listed in the Table S5, the 
best model included three SNPs: (1) rs62355902 – conditional P-value (P-
cond)=8.6x10-26; (2) rs113317823 - P-cond=2.8x10-5 and (3) rs11949391 - P-
cond=9.7x10-5. No significant evidence for heterogeneity was observed among odds 
ratios (ORs) for these SNPs among studies of European ancestry (minimum 
observed P-het=0.14 and maximum l2 = 19.3% for SNP rs11949391 - Figure S2). 
Each SNP remaining in the conditional analysis model indicates the existence of a 
separate genetic risk signal (previously defined23 as an Independent set of 
Correlated Highly Associated Variants – iCHAV), each of which will contain at least 
one directly causal variant.  
 
The most significantly associated variant overall, is rs62355902 (OR (per minor 
allele) =1.21, 95% CI 1.19-1.24; P-trend=9.5×10-49). This is the most significant of 15 
strongly correlated SNPs (r2>0.93) lying within a 50Kb interval (GRCh37 positions 
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56,003,831–56,053,745; Table 1 and marked in red in Table S5), which we have 
designated as iCHAV1. These iCHAV1 SNPs all have likelihood ratios of <100:1 
relative to the best candidate SNP, rs62355902, and thus cannot be excluded from 
further analysis, remaining as strong candidate causal variants based on 
epidemiological evidence. After conditioning on iCHAV1 top SNP, rs62355902, the 
most strongly associated variant is SNP rs113317823: OR (per minor allele)=1.22, 
95% CI 1.18-1.26; P-trend=7.0x10-25; conditional OR=1.12, 95% CI 1.05-1.20; P-
cond=2.8x10-5. One hundred and seventy two variants have likelihood ratios of 
<100:1 relative to rs113317823 and these constitute iCHAV2 (highlighted in shades 
of blue and yellow Table S5). SNP rs113317823 is partially correlated with iCHAV1 
top candidate rs62355902 (r2=0.19) and this adds complexity to the subsequent 
analysis – this is explored in more detail by the haplotype analysis described below. 
 
After adjustment for the top iCHAV1 (rs62355902) and iCHAV2 (rs113317823) 
SNPs, the best remaining significantly associated SNP is rs11949391 (iCHAV3): OR 
(per minor allele)=0.91, 95% CI 0.89-0.94; P-trend=9.4×10-12; and conditional 
OR=0.95, 95% CI 0.92-0.98; P-cond=9.7×10-5.  Four other SNPs have likelihood 
ratios of <100:1 relative to rs11949391 and are highly correlated with rs11949391 
(r2≥0.95) but not with either of the top iCHAV1 or iCHAV2 SNPs (r2<0.04, marked in 
yellow in Table S5, listed in Table 1) and these are thus candidate causal variants 
for iCHAV3.  
 
Effects on Estrogen Receptor-positive (ER+) and negative (ER-) tumor 
subtypes 
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Candidate causal SNPs in iCHAV1 are associated with risks of both ER+ and ER- 
disease (Table 1). However the OR is greater for ER+ (rs62355902 OR=1.24, 95% 
CI 1-21-1.27) than ER- disease (OR=1.10, 95% CI 1.05-1.15; P-difference=1.5x10-5; 
Table 1). By contrast, the minor alleles of candidate causal SNPs in iCHAV3 are 
protective against ER+ tumor development (rs11949391 OR=0.90, 95% CI 0.87-
0.93; P=1.9x10-10) but have no apparent effect on ER- tumor risk (OR=1.01, 95% CI 
0.96-1.06; P=0.66; P-difference=6.5x10-5; Table 1). The lead SNP in iCHAV2, 
rs113317823, remains significantly associated with ER+ tumor risk (P-cond=9.7x10-
5, after adjustment for rs62355902) but not with ER- tumor risk (P-cond=0.099), but 
the difference in the OR by ER subtype is only borderline significant (P-
difference=0.02; Table 1).  
 
Effects of haplotypes on breast cancer risk 
While iCHAVs 1 and 3 represent sets of highly correlated SNPs (r2>0.93) with the 
lead SNP), the set of 173 SNPs, labeled iCHAV2, includes three subsets, defined 
according to their correlations with rs113317823 (iCHAV2) and rs62355902 
(iCHAV1): these subsets are iCHAV2a - lead SNP rs113317823 - representing 90 
SNPs correlated with rs113317823 (r2>0.53) and with iCHAV1 SNP rs62355902 
(r2=0.19-0.29), marked in mid blue Table S5; iCHAV2b - lead SNP rs62355899 
representing 66 SNPs, which are independent of rs113317823 (r2≤0.01) but 
correlated with rs62355902 (r2=0.59-0.62) (conditional OR=0.90, 95% CI 0.86-0.95; 
P-cond=3.0x10-5), marked in Table S5 in teal; and iCHAV2c - lead SNP rs7721581 - 
representing 17 SNPs that are modestly correlated with rs113317823 (r2=0.14-0.16) 
but independent of rs62355902 (r2≤0.01) (conditional OR=0.96, 95% CI 0.93-0.98; P-
cond=4.8x10-4) marked in Table S5 in pale blue.  
27 
 
 
To further clarify these association signals, we performed haplotype analyses, based 
on the lead SNPs from iCHAVs 1, 2a, 2b, 2c and 3. These five SNPs define seven 
common haplotypes (Table 2). Two of these: h5, which carries the risk alleles of 
iCHAV1, iCHAV2a and iCHAV2b; and h6, which carries the risk alleles of iCHAV1 
and iCHAV2b, are strongly associated with risk, with the risk being higher for 
haplotype h6 (P=1.66x10-29). These results are consistent with the observation that 
SNPs in iCHAV1 are the most strongly associated with risk. They are also consistent 
with a model in which either a SNP in iCHAV2a or iCHAV2c (in combination with 
iCHAV1) increases risk, or a SNP in iCHAV2b reduces risk.  These hypotheses are 
difficult to distinguish since the iCHAV1 risk allele never occurs alone – it occurs in 
combination with either iCHAV2a/iCHAV2c or with iCHAV2b, but not both. Some 
support for the iCHAV1+iCHAV2a hypothesis is provided by the fact that haplotypes 
h3 and h4, which carry the risk alleles for iCHAV2a but not iCHAV1, though rare, are 
associated with an increased risk. Evidence against the iCHAV1+iCHAV2c 
hypothesis is provided by the fact that h1, which carries the risk allele for iCHAV2c 
alone, is not associated with an increased risk. These observations are consistent 
with the regression analyses, in which iCHAV2c is less likely than iCHAV2a or 
iCHAV2b SNPs to harbour a causal variant, (likelihood ratio ~30:1, after adjustment 
for iCHAV1). Haplotype h2, which carries the minor allele of iCHAV3 SNP 
rs11949391, was associated with a reduced ER+ (though not ER-) breast cancer 
risk, consistent with the effect of the iCHAV3 SNP in the regression analysis. 
 
We conclude that, at least, one of the 90 SNPs in iCHAV2a (positions 56,001,002-
56,270,717) or one of the 66 SNPs in iCHAV2b (positions 55,998,085-56,183,743) 
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are causally related to risk, together with a variant in iCHAV1 and a variant in 
iCHAV3.  
 
Risk associations in Asian and African-American studies  
We tested all genotyped and imputed SNPs with MAF>0.02 and imputation r2>0.3 in 
the nine Asian studies (6,269 cases and 6,624 controls; SNPs n=1045) and the two 
African-American studies (1,116 cases and 932 controls; SNPs n=1601) for 
association with overall breast cancer risk. None reached genome-wide levels of 
significance (P<5x10-8) but the lead SNPs of each iCHAV display compatible effects 
in all three ethnic groups. This is most apparent for iCHAV2a SNP rs113317823: 
(European–unadjusted) OR=1.22, 95% CI 1.18-1.26; P-trend=7.0×10-25; (Asian) 
OR=1.19, 95% CI 1.11-1.27; P-trend=1.4×10-5; (African-American) OR=1.04, 95% CI 
0.77-1.31; P-trend=0.78, Table S6. 
 
Identification of putative regulatory elements (PREs) that interact with the 
MAP3K1 promoter  
After the epidemiological analyses, 15 iCHAV1, 90 iCHAV2a, 66 iCHAV2b and 5 
iCHAV3 variants remain as strong causal candidates (Figure 1A and Table S7), 
whereas the data provide weaker support for iCHAV2c being causal. As iCHAV2a 
and 2b were comprised of a large number of variants, we prioritized these for 
functional analysis using a threshold of P-cond<1x10-4 and focused on the remaining 
30 iCHAV2a and 10 iCHAV2b variants, in addition to the iCHAV1 and iCHAV3 
candidates (Table 1). Next we examined whether these 62 iCHAV variants coincide 
with PREs that may affect gene expression. 
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Using publicly available ENCODE chromatin immunoprecipitation sequencing (ChIP-
seq) data from MCF7 and HMEC cells, we identified regions marked by histone 
modifications associated with transcriptional enhancers (mono- or di-methylation of 
H3 lysine 4 (H3K4Me1 and H3K4Me2) and acetylation of H3 lysine 27 (H3K27Ac)) or 
bound by ER, FOXA1 or GATA3, transcription factors known to play a role in breast 
cancer. Next, we mined RNA polymerase II ChIA-PET (chromatin-interaction 
analysis with paired-end tag sequencing) data, previously generated in MCF7 
cells,24,25 and identified multiple long-range chromatin interactions between discrete 
regions of the iCHAV loci and the promoter of MAP3K1 (Figure S3). Consequently, 
we performed chromosome conformation capture (3C) experiments to analyze 
interactions between the MAP3K1 promoter and these regions within 5q11.2. Using 
3C in a normal mammary epithelial cell line, Bre-80, we found several regions that 
interact with the MAP3K1 promoter (Figure 2C). Similar 3C profiles were observed 
in two ER cell lines (MCF7 and T-47D) and in ER MDA-MB231 breast cancer 
cells. (Figure S4).  
 
PREs were defined as the loci encompassing functional elements identified from the 
ENCODE data within a MAP3K1 promoter interacting region. This analysis revealed 
four PREs (A-D) that coincide with the iCHAV candidates prioritized for functional 
analyses (Figure 2). Consistently, ENCODE ChIA-PET data demonstrates that all 
four PREs interact with the MAP3K1 promoter (Figure S3A) but not with the 
promoters of other nearby genes in MCF7 cells (Figure S3B). It should be noted that 
all four PREs contain iCHAV2a or 2b variants (P-cond>1x10-4) that were not 
prioritized for functional analyses but could not be excluded as causal candidates 
after the log likelihood testing (Figure 2A). Furthermore, additional PREs, some 
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containing such iCHAV2a or 2b variants, are apparent at this locus (Figure 2). 
Twenty six percent of the 62 iCHAV variants, prioritized for functional analyses, are 
coincident with a PRE. This is an enrichment of the 16% of SNPs at this locus with 
MAF in the range of the prioritized iCHAV variants (dbSNP 138, MAF=0.04-0.18, 
accessed through the UCSC Genome Browser) that are located in a PRE. 
  
The risk alleles of iCHAV1 candidates rs74345699 and rs62355900 further 
induce PRE-C enhancer activity after estrogen stimulation 
For functional analysis of iCHAV1, we focused on seven of the 15 candidate causal 
variants, coincident with a PRE (PREs A-C; Figure 2). We first examined the effects 
of these PREs on MAP3K1 promoter activity by cloning the relevant genomic regions 
into luciferase reporter gene constructs containing the MAP3K1 promoter. All three 
of the PREs had effects on MAP3K1 promoter activity: PRE-A acted as a silencer 
and reduced promoter activity by 62% (P=0.006) in Bre-80 cells (Figure 3A) with a 
similar but non-significant trend (P=0.056) in MCF7 cells (Figure S5A). A subregion 
of PRE-B, termed PRE-B1, containing two candidate variants acted as an enhancer 
in Bre-80 cells, increasing promoter activity by 42% (P=0.047; Figure 3B), but had 
no significant effect in MCF7 cells – indicating that PRE-B1 may function in specific 
breast cell types (Figure S5B). PRE-C acted as an enhancer and increased 
MAP3K1 promoter activity by 90% (P=0.034) in MCF7 (Figure 3C) and 77% 
(P=0.034) in Bre-80 (Figure S5D) cells. Introduction of the iCHAV1 minor alleles into 
the PRE-A, PRE-B1 and PRE-C reference constructs did not detectably alter 
MAP3K1 promoter activity (Figure 3A-C; S5A-B and D). 
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ChIP-seq data from the ENCODE project indicate that at least two different 
transcription factors implicated in estrogen signaling, FOXA1 and ER-, bind within 
PRE-B1 and PRE-C, respectively (Figure 2B). We thus tested whether the iCHAV1 
candidates within PRE-B1 and PRE-C confer estrogen dependent effects on 
MAP3K1 promoter activity. We first confirmed that MAP3K1 expression is up-
regulated by estrogen stimulation (Figure S6). Then, using reporter assays, we 
examined the effects of estrogen induction on PRE-B1 and PRE-C by measuring the 
changes in MAP3K1 promoter activity between estrogen stimulated and 
unstimulated cells. We showed that the PRE-C enhancer containing the protective 
(major) alleles (Figure 3D), but not PRE-B1 (Figure S5C), has a significant induction 
in activity, compared with the promoter construct (72%, P=0.012), after estrogen 
stimulation. Compared to this reference PRE-C enhancer, induction was 23% 
(P=0.032) and 15% (P=0.011) greater in PRE-C enhancers containing the risk 
(minor) alleles of iCHAV1 candidate SNPs, rs74345699 and rs62355900, 
respectively (Figure 3D). Of note, neither of these candidates significantly affected 
MAP3K1 promoter activity in the absence of estrogen.  
 
The risk allele of iCHAV2a candidate rs16886397 in PRE-D enhances MAP3K1 
promoter activity 
Of the 30 candidate causal variants for iCHAV2a at P-cond<1x10-4, one variant, 
rs77371588, coincided with a PRE (Figure 2) and we thus prioritized this SNP for 
functional analysis. Using luciferase reporter assays, we demonstrated that the 
reference PRE-D acted as an enhancer of the MAP3K1 promoter in Bre-80 cells, 
increasing MAP3K1 promoter activity by 69% (P=0.013; Figure S7A). The PRE-D 
enhancer containing the risk (minor) allele of rs77371588 had 23% greater enhancer 
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activity than the reference PRE-D, but this effect did not reach statistical significance 
(P=0.103; Figure S7A). By contrast the same PRE-D reference construct did not 
impact MAP3K1 promoter activity in MCF7 cells nor did the introduction of the risk 
allele of rs77371588 into PRE-D significantly alter its activity (Figure 3E). As we had 
generated the PRE-D construct it was straightforward to test rs16886397, an 
additional iCHAV2a causal candidate located in PRE-D that did not reach the 
threshold for the functional prioritization (P-cond<1x10-4)  but did pass the likelihood 
ratio  threshold of <100:1 for defining the causal iCHAV candidates. In MCF7 cells, 
the construct containing the minor (risk) allele of rs16886397 had 21% (P=0.049) 
greater MAP3K1 promoter activity than the reference PRE-D (Figure 3E) and, thus, 
rs16886397 appears to confer enhancer activity on PRE-D. In Bre-80 cells, in 
contrast, the minor allele of rs16886397 had no effect on PRE-D activity (Figure 
S7A). 
 
The minor allele of iCHAV2b candidate, rs62355881, increases PRE-B2 
enhancer activity  
Of the ten iCHAV2b candidates at P-cond<1x10-4, three variants were coincident 
with PRE-B and two flanked the boundaries of PRE-C (Figure 2). We prioritized the 
three variants in PRE-B as these were the most compelling functional candidates 
due to their central location in several functional elements (Figure 2B). Using 
reporter assays, we demonstrated that the reference PRE-B2 construct (a subregion 
of PRE-B containing the iCHAV2b variants) acted as enhancer and increased the 
activity of the MAP3K1 promoter by 152% (P=0.032) and 143% (P=0.048) in MCF7 
and Bre-80 cells, respectively (Figure 3F). The introduction of the minor (potentially 
protective) allele of the iCHAV2b candidate rs62355881 into the reference PRE-B2 
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construct led to a 29% (P=0.017) increase in the enhancer activity of PRE-B2 in 
MCF7 cells and the haplotype construct containing the minor alleles of all three 
iCHAV2b candidates demonstrated a similar effect (P=0.030; Figure 3F). However, 
these effects were not seen in Bre-80 cells, indicating another cell type specific 
effect, nor did the other iCHAV2b candidates have any effect on PRE-B2 activity in 
either cell line (Figures 3F and S7B). 
 
The protective allele of iCHAV3 candidate, rs17432750, reduces PRE-B3 
enhancer activity and GATA3 binding 
Of the five iCHAV3 candidates, we focused on two variants coincident with PRE-B3 
(Figure 2B), for functional analysis. Using reporter assays, we demonstrated that the 
reference PRE-B3 construct (a third subregion of PRE-B), containing the risk (major) 
iCHAV3 alleles, increased MAP3K1 promoter activity by 166% (P=0.041; Figure 4A) 
and 110% (P=0.035; Figure S8A) in Bre-80 and MCF7 cells, respectively. Reversing 
the orientation of PRE-B3 in the reporter gene construct had no effect on its activity 
in either cell line (Figure S8B and C), indicating that it acts as a typical enhancer. 
Next, we introduced the protective (minor) alleles of the iCHAV3 candidates into the 
reference PRE-B3 construct. The protective A allele of rs17432750 had a repressive 
effect and reduced PRE-B3 enhancer activity by 43% (P=0.024; Figure 4A) in Bre-
80 cells. The same allele had a similar but non-significant effect (P=0.150) in MCF7 
cells (Figure S8A). By contrast the protective allele of the second iCHAV3 
candidate, rs11956804, had no significant effect on enhancer activity in either cell 
line (Figures 4A and S8A). The haplotype construct containing both iCHAV3 
variants also had no significant effect on enhancer activity either (Figures 4A and 
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S8A), suggesting the possibility of an interaction between the two iCHAV3 minor 
alleles in this construct. 
 
We observed from MCF7 ChIP-seq data that a region containing rs17432750 binds 
the GATA3 transcription factor (Figure 2B) and that the sequence around 
rs17432750 shows homology to the GATA3 position weight matrix (Figure 4B). 
Using GATA3 ChIP-assays, followed by qPCR detection, we confirmed that there 
was a consistent 2-fold enrichment of the sequence surrounding this SNP in 
precipitated DNA, when compared to a CCND1 negative control (Figure 4C). We 
also tested the allele-specificity of GATA3 binding using a Taqman genotyping assay 
for rs17432750 on ChIP samples from MCF7 cells. The allelic discrimination plot of 
these data showed an enrichment of the risk (major) C allele in the GATA3 ChIP 
samples (Figure 4D). The ratio of the two alleles in three independent ChIP 
experiments indicated a 3.7-fold greater GATA3 binding to the risk C allele, 
compared to the protective A allele, in MCF7 cells.  
 
To determine whether differential GATA3 transcription factor binding may explain the 
effects of rs17432750 in the reporter assays, we knocked down GATA3 using siRNA 
and found the enhancer activity of the reference PRE-B3 construct, containing the 
risk C allele, was reduced by 33% in Bre-80 cells (P=0.001; Figure 4E). GATA3 
knockdown had no effect on the construct containing the protective A allele of 
(rs17432750) or the MAP3K1 promoter alone (Figure 4E). Diminished GATA3 
binding to the protective A allele thus appears to be responsible for the decrease in 
PRE-B3 enhancer activity observed under basal conditions (Figure 4A).  
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Expression quantitative trait (eQTL) analyses 
Given the findings of these functional studies, an obvious hypothesis is that the 
candidate causal variants in the iCHAVs would be associated with differences in 
expression of MAP3K1, and possibly other local genes in normal breast cells.  We 
therefore explored potential eQTL associations of all locus SNPs with genes lying 
within ~1 Mb of the locus in 135 normal breast tissue samples from the METABRIC 
study and 56 further normal breast samples from TCGA. Summary results for 
representative SNPs from the three iCHAVs are presented in Table S8.  None of the 
iCHAV-representative SNPs show detectable differences in MAP3K1 expression in 
this dataset. This locus has a positive control eQTL: SNP rs832402 is the most 
strongly associated SNP with SETD9 expression in both METABRIC (P=5.93x10-9) 
and TCGA (P=1.96x10-7), but it is not a strong candidate breast cancer risk SNP (P-
cond=1.46x10-3). The positive control SNP is in iCHAV2c (correlated with lead SNP, 
rs7721581 at r2=0.74) and SNP rs7721581 is consequently also associated, 
although less significantly, with SETD9 expression (METABRIC P=4.38x10-8; TCGA 
P=2.78x10-4). However, as none of the other representative iCHAV SNPs are 
associated with SETD9 expression, it appears unlikely that detectable SETD9 
expression differences in normal breast cells are the underlying cause of breast 
cancer generated by the candidate functional variants we have identified. 
 
Discussion 
In this fine scale mapping study, we have found clear evidence for at least three 
independent breast cancer risk variants in European women: SNPs in iCHAV1 and 
iCHAV2, each have the greatest effects on breast cancer in the unadjusted analysis, 
with minor alleles conferring increased risks of 25-30% for ER+ and ~10% for ER- 
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tumor-development, while the minor alleles of SNPs in iCHAV3 have a protective 
effect of ~10% against ER+ breast cancer, although no apparent effect on ER- tumor 
risk (Table 1). The originally detected GWAS tag SNP, rs889312, is most correlated 
with iCHAV1 (r2=0.5) and can be excluded from causality within iCHAV1 with a 
likelihood ratio of >1021:1. Within iCHAV2, we have additionally found evidence of 
three subsets of variants with a range of effects: iCHAVs 2a, 2b and 2c. The 
epidemiological analyses suggest iCHAV2c is least likely to be causally related to 
risk and we conclude that at least one of the variants in iCHAV2a or iCHAV2b is 
functional. It should be noted that the correlations between candidate causal SNPs in 
iCHAVs 1 and 2 have added a level of complexity to this analysis and its 
interpretation that we have not recognized in previous fine-scale mapping studies of 
breast cancer risk loci.  
 
We have separately identified at least four PREs within the 5q11.2 locus that contain 
iCHAV candidate variants and interact with the MAP3K1 promoter in normal and 
cancer mammary epithelial cells. 3C analysis indicates that there are long range 
chromatin interactions between these PREs and the MAP3K1 promoter, while 
interactions between the PREs and the promoters of other nearby genes are not 
evident from available ChIA-PET studies.24,25 Although we cannot rule out 
interactions between the iCHAVs and the promoters of other genes in the region 
such as SETD9 or MIER3, a proposed candidate gene for this risk locus,26 we 
propose that MAP3K1 is the likely target gene of the 5q11.2 breast cancer 
susceptibility locus. Consistent with this proposition and our analyses, Corradin et al. 
identified an enhancer (chr5:56052477-56053943) coincident with the element we 
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have termed PRE-C that is predicted to regulate MAP3K1, based on correlation of 
cell-type specific H3K4me1 modification and MAP3K1 expression data.27 
  
Our reporter assays indicate that PREs B, C and D act as enhancers while PRE-A is 
a silencer of the MAP3K1 promoter. Having identified these regulatory elements we 
have investigated whether the iCHAV candidate causal variants, within these PREs, 
detectably modify their regulatory activity. We found that the risk alleles of two 
iCHAV1 candidates, rs74345699 and rs62355900, in the PRE-C enhancer, act to 
further induce MAP3K1 promoter activity in breast cancer cells under estrogen 
stimulation; the risk allele of iCHAV2a candidate, rs16886397, in PRE-D confers 
enhancer activity on this PRE for MAP3K1 promoter activity in breast cancer cells; 
the potentially protective allele of iCHAV2b candidate, rs62355881, in the PRE-B2 
enhancer, increases MAP3K1 promoter activity in breast cancer cells; while the 
protective allele of iCHAV3 SNP rs17432750 diminishes the enhancer activity of 
PRE-B3 for the MAP3K1 promoter in these cells.  
 
Due to experimental constraints, we have only been able to examine the functions of 
a minority of the iCHAV causal candidates and, thus, we cannot exclude the 
presence of more functional variants across the recognizable iCHAVs. Of the 
candidates we have examined in reporter gene assays, four support a hypothesis 
that alleles, which increase MAP3K1 expression, also increase breast cancer risk. 
Currently, the allelic effects of a fifth candidate, iCHAV2b SNP rs62355881, may be 
inconsistent with this hypothesis as the conditional analysis suggests iCHAV2b has a 
protective effect. However, we do not have clear epidemiological evidence that 
iCHAV2b has an individual effect on risk: iCHAV2b is only observed in the presence 
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of iCHAV1, which in combination on the same haplotype act to increase breast 
cancer risk, and we could not test such iCHAV haplotype effects in reporter gene 
assays, given the number of candidates and the size of the region they encompass.  
 
Consistent with our hypothesis that candidate causal risk alleles act by increasing 
transcriptional activation of MAP3K1, Godde et al. have recently demonstrated that 
up-regulation of MAP kinase activity in mouse mammary basal progenitor cells is 
associated with ductal hyperplasia and accelerated tumor progression.28 This 
hypothesis is also supported by one known function of MAP3K1 protein (MEKK1): 
knockdown of MAP3K1 in human breast cancer cells reduces tumor invasiveness 
and progression in a mouse model.29 Furthermore, studies have shown that MEKK1 
has an anti-apoptotic effect and enhances cancer cell survival,30,31 although, upon 
stress stimulus, caspase cleavage of the protein generates a fragment that plays a 
pro-apoptotic role.6,7 These dual functions of MEKK1 suggest it has a complex role in 
cell fate decisions. In this context, it is intriguing that somatic MAP3K1 driver 
mutations, found in tumor sequencing studies, are mostly truncating and are 
predicted to disrupt MEKK1 signaling,11 since inactivation of the kinase domain at the 
protein terminus reduces apoptotic responses in cells exposed to stress.7 Thus, it 
appears that germline cancer risk alleles act by increasing MAP3K1 expression, but 
once a tumor has developed, somatic mutations drive cancer progression by 
disrupting MEKK1 signaling within the tumor. Dysregulation of MAP3K1 expression 
or MEKK1 function may thus promote tumorigenesis by perturbing a balance 
between cell apoptosis and survival. Similar conflicting effects of germline risk 
variants and somatic mutations have been observed at other breast cancer risk loci. 
For example, CCND1 is frequently amplified in breast tumors and here 
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overexpression appears to play an important role in breast cancer pathogenesis,32  
even though germline breast cancer risk alleles at 11q13 reduce CCND1 
transcriptional activity.17 Amplification of TERT [MIM 187270] is also common within 
breast and other tumors33 but, again, germline breast cancer risk alleles reduce 
TERT transcriptional activity.34 These observations therefore challenge the notion 
that variants at loci such as 5q11.2 act in the same manner as somatic tumor driver 
mutations to confer germline risk of tumor development. 
 
iCHAV1 spans multiple PREs (PREs 1, 2 and 3) and is consistent with a recent 
proposal that genetic susceptibility to common diseases can be explained by multiple 
enhancer variants in linkage disequilibrium, each with modest effects on gene 
expression, which cooperatively act to alter gene expression.27 There is also some 
suggestion from the haplotype data that iCHAV2a, which is in linkage disequilibrium 
(r2=0.19-0.29) with iCHAV1, may in combination with iCHAV1 have a cooperative 
effect on risk. The modest effect sizes observed in the reporter assays for iCHAV1 
and 2a variants may be a consequence of the fact that, due to size limitations of 
reporter gene constructs, we could not examine these variants in combination. 
 
Some SNP effects in our reporter assays were suggestive of cell-line and stimulus-
dependence, highlighting the importance of cellular and environmental context when 
assessing SNP functionality.23 Similarly, we defined our PREs on the basis of 
chromatin modification and conformation states, both of which can change during 
development or in response to stimulus. Additionally, the effects of some SNPs may 
not have been observed because plasmid reporter gene constructs do not reflect the 
native genomic context nor the chromatin or methylation state of genomic DNA. The 
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chromatin state of transiently transfected DNA, for example, is considered to be 
more open and disorganized than the corresponding chromatin in the native genomic 
context and may not have the repressive chromatin structures, found in genomic 
DNA, that inhibit binding of ubiquitous transcription factors.35 A disorganized 
chromatin state may explain the inconsistent effect of rs17432750 in the PRE-B3 
constructs (Figure 4A). The abrogation of the effect of rs17432750 in the haplotype 
construct suggests some interaction or cooperative effect of the minor alleles of 
rs17432750 and rs11956804 to enhance promoter activity. This effect may be 
possible due to the more open and permissive chromatin structures associated with 
transfected plasmid DNA. 
 
It is noteworthy that, in available normal breast tissue, the top candidate causal 
variants show no association with MAP3K1 expression, although iCHAV2c variants 
are associated with significant differences in SETD9 mRNA levels. Similarly, normal 
breast tissue eQTL studies with strong candidate causal variants at the 
11q13,1710q26,15 2q3536 and 5p15.3334 breast cancer loci have indicated that 
available normal breast samples may be inappropriate for these studies. Sample 
sizes are large enough to detect significant eQTLs at these loci but those detected 
do not appear to drive breast cancer risk. It is possible that tissue heterogeneity, 
developmental stage or stimulus-dependent effects prevent the detection of risk 
driving eQTLs in currently available normal breast samples. Indeed, the finding that 
up-regulation of MAP kinase activity in mammary progenitor cells is associated with 
mammary tumorigenesis28 suggests that increased MAP3K1 expression in specific 
breast cell populations, possibly at a specific point in time, could drive breast cancer 
risk. 
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Transcription factor binding studies indicate that the C (risk) allele of rs17432750 
preferentially binds GATA3 over the A (protective) allele. Increased binding of the C 
allele by GATA3 appears to explain the activity of the PRE-B3 enhancer in which it is 
located (Figure 4E). These findings suggest that SNP rs17432750 is a strong causal 
candidate for the protective effect of iCHAV3. The transcription factor GATA3 has 
multiple regulatory roles and can affect histone modifications associated with 
enhancers, and the binding of other transcription factors related to breast cancer 
such as ER- and FOXA1.37 We have previously identified GATA3 to be a mediator 
of breast cancer risk across multiple loci38 and specifically at the 11q13 locus.17 
 
In conclusion, we have found evidence for the existence of at least three breast 
cancer risk iCHAVs that partially coincide with four MAP3K1 gene regulatory 
elements at 5q11.2. Genetic epidemiological studies within BCAC reduced the 
catalogue of potentially causal variants from 909 to 193 candidates within five 
iCHAVs, of which at least three must be functional. Functional studies on candidates 
that lie within the identified regulatory elements have shown that the effects of strong 
candidate cancer risk alleles, in iCHAVs 1, 2a and 3, are compatible with the 
hypothesis that they act via increased expression of MAP3K1. Moreover, the 
function of MAP3K1 protein (MEKK1) suggests that increased expression may alter 
the balance between apoptosis and cell survival in breast cancer cells, thus 
explaining the risks conferred by the candidate alleles. 
 
Supplemental Data 
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Supplemental Data include Acknowledgements, nine figures and eight tables. 
 
Web Resources 
1,000 Genomes Project: http://www.1000genomes.org/ 
R: http://www.bios.unc.edu/~weisun/software/eMap 
UCSC Genome Browser: http://genome.ucsc.edu 
Online Mendelian Inheritance in Man: http://www.omim.org 
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Figure Titles and Legends 
 
 Figure 1. Genetic mapping and chromatin state of the 5q11.2 locus. (A) 
Manhattan plot of overall breast cancer risk in Europeans at the 5q11.2 locus. SNPs 
are plotted based on their chromosomal position on the x axis and P-values (log10 
values) for association. The span of the iCHAVs in terms of chromosomal location 
and P-value is displayed using shading and candidate causal variants from the 
iCHAV are colored black. The lead SNPs from each iCHAV, the original GWAS tag 
SNP (rs889312) and the three genes present in the region are shown. The dotted 
line intersects the y-axis at P=10-8 and indicates conventional genome-wide 
significance. (B) The chromatin state of the 5q11.2 locus in human mammary 
epithelial cells (HMECs) is shown using ENCODE ChIP-seq data from H3K4me3, 
H3K4me2, H3k4me1 and DNaseI studies accessed from the UCSC Genome 
Browser (http://genome.ucsc.edu). Transcription factor (TF) binding from ENCODE 
ChIP-seq studies of 161 TFs in 91 cell lines is also displayed.  
 
Figure 2. Candidate causal variants are located in PREs that interact with the 
MAP3K1 promoter. (A) The candidate causal variants associated with breast 
cancer risk from iCHAVs 1, 2a, 2b and 3 were mapped to PREs at the 5q11.2 locus. 
(B) PREs (highlighted) were identified using ChIP-seq data (H3K4Me1 studies in 7 
ENCODE cell lines (GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK and NHLF); 
H3K4Me1 and H3K4Me2 in MCF7 and HMEC cells; transcription factors ER-, 
FOXA1 and GATA3 in MCF7 cells) accessed from the UCSC Genome Browser. 
Regions cloned into reporter gene constructs are also shown. (C) 3C analysis of 
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interactions between EcoRI fragments at the 5q11.2 locus, encompassing the PREs 
coincident with candidate causal variants, and the MAP3K1 promoter in Bre-80 cells 
(error bars represent standard deviation and a representative graph is shown).  
 
Figure 3. Risk (minor) alleles of iCHAV1 and iCHAV2a SNPs enhance MAP3K1 
promoter activity in luciferase reporter assays. PRE-A, PRE-B, PRE-C and PRE-
D regions containing the major allelic variants of iCHAV1, iCHAV2a and 2b SNPs 
were cloned downstream of a MAP3K1 promoter-driven luciferase construct 
(Promoter) to create reference (Ref) PRE constructs. Minor allelic variants of the 
iCHAV1, iCHAV2a and 2b SNPs were engineered into the constructs and are 
designated by the rs ID of the corresponding SNP. Constructs containing minor 
allelic haplotypes (Haplotype) were also generated. Cells were transiently 
transfected with each of these constructs and assayed for luciferase activity after 24 
h. Panels (A-B) show results from assays of PRE-A and PRE-B1, respectively, in 
Bre-80 cells. Panels (C, E and F) show results from assays of PRE-C, PRE-D and 
PRE-B2 constructs, respectively, in MCF7 cells under basal conditions. Panel (D) 
shows results after estrogen induction of MCF7 cells. For each reporter construct in 
this assay, the luciferase activity of estrogen treated cells was normalized to the 
activity of the corresponding vehicle treated cells. Error bars denote standard error of 
the mean (SEM) from three experiments performed with triplicates. P-values were 
determined by repeated-measures ANOVA followed by Dunnett’s multiple 
comparisons test (*P<0.05 and **P<0.01). 
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Figure 4. The protective (minor) allele of iCHAV3 SNP rs17432750 
demonstrates diminished PRE-B3 enhancer activity in luciferase reporter 
assays and reduced GATA3 binding in ChIP analysis. (A) The PRE-B3 region 
containing the major allelic variants of iCHAV3 SNPs was cloned downstream of a 
MAP3K1 promoter-driven luciferase construct (Promoter) to create reference (Ref) 
PRE constructs. Minor allelic variants of iCHAV3 SNPs were engineered into the 
constructs which are designated by the rs ID of the corresponding SNP. A construct 
containing the minor allelic haplotypes (Haplotype) was also generated. Bre-80 cells 
were transiently transfected with each of these constructs and assayed for luciferase 
activity after 24 h. Error bars denote SEM from three experiments performed in 
triplicate. P-values were determined by repeated-measures ANOVA followed by 
Dunnett’s multiple comparisons test (*P<0.05). (B) Position Weight Matrix of GATA3 
is shown relative to the negative strand of the sequences surrounding rs17432750. 
(C) GATA3 ChIP assays demonstrate enrichment of rs17432750 relative to the 
CCND1 negative control. A GATA3 site from the ER-α enhancer was included as 
positive control. Results from two biological repeats are shown and error bars denote 
SD of three technical repeats. (D) Genotyping of rs17432750 in MCF7 genomic DNA 
versus MCF7 GATA3-ChIP DNA. Homozygous cell lines ZR751 (C/C), T47D (C/C), 
MDA-MB-468 (A/A) and no template controls (NTC) were included as reference for 
the assay. The risk (major) C allele is preferentially precipitated in the ChIP 
experiment. (E) Luciferase assay in Bre-80 cells showing the effect of GATA3 siRNA 
silencing on the activity of the MAP3K1 promoter alone (Promoter) and with PRE-B3 
constructs containing the C allele (ref PRE-B3) and protective A (minor) allele 
rs17432750 (rs17432750). Error bars denote SEM from three experiments 
performed in triplicate. P-values were determined by two-way repeated-measures 
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ANOVA followed either by Sidak’s multiple comparisons test (to analyze the effect of 
GATA3 knockdown within constructs) or Dunnett’s multiple comparison test (to 
analyze differences in activity between constructs). (*P<0.05, **P<0.01 and 
***P<0.001). The level of GATA3 knockdown is shown in Figure S9.  
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iCHAV SNP 
Chr 
Position 
(GRch37) 
Alleles 
(major/
minor) 
MAF 
r
2
 with 
lead 
iCHAV1 
SNP 
Imp 
r
2
 
Overall breast cancer risk ER-positive breast cancer risk ER-negative breast cancer risk 
ER-
positive 
/negative 
OR  (95%CI) P-trend P-cond OR (95%CI) P-trend P-cond OR (95%CI) P-trend P-cond 
 
P-diff 
1 rs10461612 56003831 G/C 0.18 0.96 0.97 1.21 (1.18-1.23) 1.08E-47  1.23 (1.20-1.26) 1.71E-43  1.09 (1.04-1.14) 4.13E-04  1.47E-05 
1 rs7709971 56007339 G/A 0.18 0.96 0.97 1.21 (1.18-1.23) 1.05E-47  1.24 (1.21-1.27) 1.33E-43  1.09 (1.04-1.14) 4.86E-04  1.17E-05 
1 rs7714232 56011357 A/T 0.18 0.94 0.99 1.21 (1.18-1.23) 4.76E-48  1.23 (1.20-1.26) 5.09E-44  1.09 (1.04-1.14) 5.64E-04  8.03E-06 
1 rs12653202 56016918 A/C 0.18 0.94 1 1.21 (1.18-1.23) 2.17E-47  1.23 (1.20-1.26) 7.65E-42  1.09 (1.04-1.14) 5.04E-04  2.68E-05 
1 rs59270457 56017887 T/G 0.18 0.96 1 1.21 (1.18-1.23) 1.22E-47  1.23 (1.20-1.26) 1.02E-42  1.09 (1.04-1.14) 4.48E-04  1.76E-05 
1 rs61055995 56019064 A/T 0.18 0.96 1 1.21 (1.18-1.23) 1.16E-47  1.23 (1.20-1.26) 7.36-E43  1.09 (1.04-1.14) 4.70E-04  1.62E-05 
1 rs16886165 56023083 T/G 0.18 0.96 1 1.21 (1.18-1.23) 1.14E-47  1.23 (1.20-1.26) 6.22E-43  1.09 (1.04-1.14) 4.56E-04  1.55E-05 
1 rs16886181 56029243 T/C 0.18 0.96 1 1.21 (1.18-1.23) 4.80E-48  1.23 (1.20-1.26) 2.87E-43  1.10 (1.05-1.15) 2.69E-04  2.26E-05 
1 chr5:56030827:I 56030827 T/TA 0.18 0.97 0.99 1.20 (1.18-1.23) 2.33E-47  1.23 (1.20-1.26) 1.27E-42  1.09 (1.04-1.14) 5.82E-04  1.24E-05 
1 rs66893416 56051596 G/A 0.18 0.99 0.97 1.21 (1.18-1.23) 1.19E-47  1.23 (1.20-1.26) 4.60E-43  1.09 (1.04-1.14) 4.42E-04  1.05E-05 
1 rs62355900 56052695 T/C 0.18 0.98 1 1.20 (1.18-1.23) 4.26E-47  1.23 (1.20-1.26) 8.93E-43  1.09 (1.04-1.14) 5.84E-04  1.21E-05 
1 rs74345699 56053479 C/T 0.18 0.99 0.99 1.20 (1.18-1.23) 5.08E-47  1.23 (1.20-1.26) 1.57E-42  1.09 (1.04-1.14) 7.01E-04  1.05E-05 
1 rs62355901 56053535 T/C 0.18 0.98 0.93 1.21 (1.18-1.24) 3.90E-47  1.24 (1.20-1.27) 5.41E-42  1.10 (1.04-1.15) 5.20E-04  1.49E-05 
1 rs62355902 
a
 56053723 A/T 0.18 - 0.95 1.21 (1.19-1.24) 9.50E-49  1.24 (1.21-1.27) 5.71E-44  1.10 (1.05-1.15) 3.02E-04  1.47E-05 
1 rs149188233 56053745 
A/AAAA
C 
0.18 0.99 0.98 1.20 (1.18-1.23) 3.92E-47  1.23 (1.20-1.26) 1.00E-42  1.09 (1.04-1.14) 6.48E-04  1.13E-05 
                                      
 
2a rs77961606 56040643 T/C 0.05 0.28 0.98 1.27 (1.22-1.31) 1.03E-28 9.21E-05 1.29 (1.25-1.34) 3.42E-25 4.55E-04 1.09 (1.01-1.18) 3.59E-02 7.58E-01 1.04E-04 
2a rs16886272 56067434 A/G 0.07 0.19 0.95 1.21 (1.17-1.25) 8.89E-24 4.14E-05 1.25 (1.20-1.29) 3.41E-23 1.01E-05 1.07 (0.99-1.14) 8.47E-02 8.08E-01 5.42E-05 
2a rs113317823
a 
56087883 T/C 0.08 0.19 0.72 1.22 (1.18-1.26) 7.00E-25 1.61E-05 1.24 (1.20-1.29) 2.02E-21 9.74E-05 1.12 (1.05-1.20) 2.56E-03 9.90E-02 1.93E-02 
2a rs77371588 56134560 G/T 0.05 0.26 0.98 1.27 (1.22-1.31) 1.36E-27 9.03E-05 1.29 (1.25-1.34) 2.01E-24 2.68E-04 1.11 (1.02-1.19) 2.11E-02 5.37E-01 3.32E-04 
2a rs60590641 56141155 G/A 0.05 0.26 0.98 1.27 (1.22-1.31) 1.16E-27 7.93E-05 1.30 (1.25-1.35) 1.08E-24 2.01E-04 1.11 (1.02-1.19) 2.10E-02 5.33E-01 3.05E-04 
2a rs61154548 56224720 C/T 0.05 0.24 0.97 1.27 (1.23-1.32) 4.32E-27 2.76E-05 1.30 (1.25-1.36) 4.03E-24 9.06E-05 1.10 (1.01-1.19) 3.65E-02 6.19E-01 3.37E-04 
2a chr5:56237882:D 56237882 
CAGTTA
AGTTTA/
C 
0.04 0.23 0.93 1.28 (1.24-1.33) 1.82E-25 8.94E-05 1.32 (1.26-1.37) 3.49E-23 1.57E-04 1.10 (1.01-1.20) 3.80E-02 6.02E-01 5.14E-04 
2a rs79565352 56251753 G/A 0.06 0.20 1 1.23 (1.19-1.27) 7.45E-24 6.46E-05 1.25 (1.20-1.29) 8.52E-20 7.69E-04 1.11 (1.03-1.19) 1.42E-02 3.04E-01 2.20E-03 
2a rs74571895 56254772 A/G 0.05 0.20 0.99 1.24 (1.20-1.28) 1.71E-24 3.62E-05 1.26 (1.21-1.30) 1.54E-20 3.99E-04 1.11 (1.03-1.19) 1.16E-02 2.70E-01 2.10E-03 
2a rs78743305 56256217 G/A 0.05 0.20 0.99 1.24 (1.20-1.28) 1.41E-24 3.28E-05 1.26 (1.21-1.30) 1.20E-20 3.54E-04 1.11 (1.03-1.19) 1.11E-02 2.64E-01 2.03E-03 
2a rs7726354 56256483 C/T 0.06 0.20 1 1.23 (1.19-1.27) 4.51E-24 5.13E-05 1.25 (1.20-1.30) 4.61E-20 5.90E-04 1.11 (1.03-1.19) 1.30E-02 2.88E-01 2.11E-03 
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2a rs79760198 56262639 T/C 0.05 0.23 0.98 1.27 (1.23-1.31) 1.39E-26 2.71E-05 1.30 (1.25-1.35) 3.04E-23 1.34E-04 1.11 (1.03-1.20) 1.74E-02 3.91E-01 1.23E-03 
2a rs79041328 56264375 A/G 0.05 0.23 0.99 1.27 (1.23-1.31) 1.48E-26 2.70E-05 1.30 (1.24-1.35) 3.42E-23 1.38E-04 1.11 (1.03-1.20) 1.60E-02 3.71E-01 1.42E-03 
2a rs6893174 56265025 C/T 0.05 0.22 1 1.26 (1.22-1.30) 
8.59E-26 4.75E-05 
1.28 (1.23-1.33) 2.83E-22 2.77E-04 1.11 (1.02-1.19) 1.88E-02 4.02E-01 1.56E-03 
2a rs113325879 56266142 G/A 0.05 0.23 0.99 1.27 (1.23-1.31) 1.30E-26 2.53E-05 1.30 (1.25-1.35) 3.73E-23 1.45E-04 1.11 (1.03-1.20) 1.52E-02 3.59E-01 1.47E-03 
2a rs142258027 56266278 G/A 0.05 0.22 0.96 1.27 (1.22-1.31) 8.33E-26 4.57E-05 1.29 (1.24-1.34) 1.83E-22 2.34E-04 1.11 (1.02-1.20) 1.97E-02 4.12E-01 1.46E-03 
2a rs113173541 56266689 C/A 0.05 0.23 0.98 1.27 (1.23-1.31) 1.34E-26 2.57E-05 1.30 (1.25-1.35) 4.05E-23 1.51E-04 1.11 (1.03-1.20) 1.52E-02 3.60E-01 1.49E-03 
2a rs78925509 56267141 A/G 0.05 0.23 0.98 1.27 (1.23-1.31) 1.41E-26 2.63E-05 1.30 (1.25-1.35) 4.38E-23 1.56E-04 1.11 (1.03-1.20) 1.55E-02 3.63E-01 1.49E-03 
2a rs73122135 56267308 G/A 0.05 0.23 0.96 1.27 (1.22-1.31) 1.93E-26 3.14E-05 1.29 (1.24-1.35) 4.03E-23 1.63E-04 1.11 (1.02-1.19) 1.98E-02 4.30E-01 1.02E-03 
2a rs80089016 56267444 G/A 0.05 0.23 0.98 1.27 (1.23-1.32) 1.43E-26 2.64E-05 1.30 (1.25-1.35) 4.61E-23 1.59E-04 1.11 (1.03-1.20) 1.54E-02 3.62E-01 1.52E-03 
2a rs73122138 56267949 G/A 0.05 0.23 0.96 1.26 (1.22-1.31) 6.61E-26 5.47E-05 1.29 (1.24-1.34) 1.54E-22 3.19E-04 1.11 (1.02-1.19) 2.27E-02 4.66E-01 1.17E-03 
2a rs80310238 56267984 C/A 0.05 0.23 0.98 1.27 (1.23-1.32) 1.45E-26 2.67E-05 1.30 (1.25-1.35) 5.00E-23 1.66E-04 1.11 (1.03-1.20) 1.55E-02 3.64E-01 1.53E-03 
2a rs77706078 56268686 G/A 0.05 0.23 0.98 1.27 (1.23-1.32) 1.40E-26 2.63E-05 1.30 (1.25-1.35) 5.05E-23 1.67E-04 1.11 (1.03-1.20) 1.52E-02 3.59E-01 1.57E-03 
2a chr5:56268884:I 56268884 
C/CTGG
GAGGT 
0.04 0.22 0.96 1.28 (1.24-1.33) 8.44E-27 1.76E-05 1.31 (1.25-1.36) 3.05E-23 1.16E-04 1.12 (1.03-1.21) 1.15E-02 3.00E-01 2.05E-03 
2a rs2408651 56268991 T/C 0.05 0.23 0.95 1.26 (1.22-1.31) 1.08E-25 6.53E-05 1.29 (1.24-1.34) 2.10E-22 3.50E-04 1.11 (1.02-1.19) 2.19E-02 4.57E-01 1.19E-03 
2a rs79459889 56269286 G/A 0.05 0.23 0.98 1.27 (1.23-1.31) 2.09E-26 3.08E-05 1.29 (1.24-1.35) 8.65E-23 2.06E-04 1.12 (1.03-1.20) 1.43E-02 3.49E-01 1.74E-03 
2a rs111773762 56269336 T/C 0.05 0.23 0.98 1.27 (1.23-1.31) 2.53E-26 3.33E-05 1.29 (1.24-1.35) 7.04E-23 1.87E-04 1.11 (1.03-1.20) 1.50E-02 3.58E-01 1.57E-03 
2a rs80097053 56269492 C/T 0.05 0.23 0.98 1.27 (1.23-1.31) 2.50E-26 3.31E-05 1.29 (1.24-1.35) 7.03E-23 1.87E-04 1.12 (1.03-1.20) 1.49E-02 3.56E-01 1.58E-03 
2a rs59536253 56269512 A/G 0.05 0.23 0.96 1.27 (1.22-1.31) 2.84E-26 3.73E-05 1.29 (1.24-1.34) 8.40E-23 2.26E-04 1.11 (1.03-1.20) 1.64E-02 3.88E-01 1.40E-03 
2a rs112032073 56270717 G/T 0.05 0.23 0.98 1.27 (1.23-1.31) 2.40E-26 3.27E-05 1.30 (1.24-1.35) 7.36E-23 1.92E-04 1.12 (1.03-1.20) 1.41E-02 3.44E-01 1.69E-03 
                                     
2b rs12659430 56032619 A/G 0.13 0.62 1.00 1.15 (1.12-1.18) 1.73E-19 4.42E-05 1.17 (1.13-1.20) 3.95E-18 1.81E-03 1.08 (1.02-1.14) 8.95E-03 6.26E-01 1.96E-02 
2b rs62355881 56033093 T/C 0.13 0.62 1.00 1.15 (1.12-1.18) 1.61E-19 4.68E-05 1.17 (1.13-1.20) 3.62E-18 1.92E-03 1.08 (1.02-1.14) 8.95E-03 6.26E-01 1.93E-02 
2b rs2113084 56033671 T/C 0.13 0.62 1.00 1.15 (1.12-1.18) 1.97E-19 4.02E-05 1.17 (1.13-1.20) 4.80E-18 1.62E-03 1.08 (1.02-1.14) 8.92E-03 6.27E-01 2.02E-02 
2b rs62355882 56045110 C/T 0.13 0.60 1.00 1.15 (1.12-1.18) 3.69E-19 7.81E-05 1.16 (1.13-1.20) 2.64E-17 1.06E-03 1.08 (1.02-1.14) 1.22E-02 5.60E-01 2.42E-02 
2b rs62355899
a 
56050465 A/G 0.13 0.62 1.00 1.15 (1.12-1.18) 2.98E-19 3.04E-05 1.17 (1.13-1.20) 5.52E-18 2.04E-03 1.08 (1.02-1.14) 1.11E-02 5.42E-01 1.86E-02 
2b rs10513090 56054065 T/C 0.13 0.62 1.00 1.15 (1.12-1.18) 1.91E-19 3.67E-05 1.17 (1.13-1.20) 2.92E-18 2.79E-03 1.08 (1.02-1.13) 1.43E-02 4.46E-01 1.32E-02 
2b rs6895844 56057940 G/A 0.13 0.62 1.00 1.15 (1.12-1.18) 7.44E-20 7.50E-05 1.17 (1.13-1.20) 1.17E-18 4.66E-03 1.07 (1.02-1.13) 1.63E-02 3.99E-01 1.08E-02 
2b rs6882255 56058171 T/A 0.13 0.63 0.97 1.15 (1.12-1.18) 3.03E-20 9.13E-05 1.17 (1.14-1.21) 8.02E-19 5.26E-03 1.08 (1.02-1.13) 1.47E-02 4.15E-01 9.86E-03 
2b rs12654584 56058415 T/G 0.13 0.62 1.00 1.15 (1.12-1.18) 5.90E-20 8.57E-05 1.17 (1.13-1.20) 8.79E-19 5.31E-03 1.07 (1.02-1.13) 1.61E-02 4.01E-01 1.01E-02 
2b rs12654176 56058487 A/G 0.13 0.62 1.00 1.15 (1.12-1.18) 4.29E-20 9.99E-05 1.17 (1.14-1.20) 8.04E-19 5.66E-03 1.08 (1.02-1.13) 1.33E-02 4.64E-01 1.19E-02 
                    
3 rs17432750 56031822 C/A 0.16 0.04 0.98 0.92 (0.89-0.94) 4.55E-11 1.61E-04 0.90 (0.87-0.93) 9.03E-11 1.48E-04 1.01 (0.96-1.06) 6.53E-01 2.44E-01 5.13E-05 
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3 rs199945768 
56033233 
CG/C 0.16 0.04 0.92 0.91 (0.89-0.94) 6.35E-11 2.66E-04 0.90 (0.87-0.93) 1.90E-10 3.09E-04 1.01 (0.96-1.06) 6.61E-01 2.49E-01 6.53E-05 
3 rs11956804 56033233 C/A 0.16 0.04 0.94 0.91 (0.89-0.94) 7.39E-11 1.86E-04 0.90 (0.87-0.93) 1.90E-10 2.05E-04 1.01 (0.96-1.06) 6.61E-01 2.22E-01 7.44E-05 
3 rs11949391
a
 56045081 T/C 0.16 0.04 1 0.91 (0.89-0.94) 9.36E-12 5.57E-05 0.90 (0.87-0.93) 1.00E-10 1.44E-04 1.01 (0.96-1.06) 8.14E-01 3.50E-01 1.27E-04 
3 rs6884514 56062614 C/T 0.16 0.04 1 0.92 (0.89-0.95) 6.04E-10 5.80E-04 0.91 (0.88-0.94) 1.90E-09 6.74E-04 1.01 (0.96-1.06) 6.15E-01 2.30E-01 1.13E-04 
 
Table 1.  iCHAVs with the strongest effects on breast cancer risk in European studies 
Single SNP risk estimates for the top candidates in each iCHAV with overall breast cancer risk and subtypes by estrogen receptor status. Results 
are given as ORs with 95% CI (using the minor variant alleles as the reference), per-allele P-trend and P-cond, (P-cond being conditional on the 
iCHAV1 lead SNP rs62355902). The ER-positive/negative P-diff is from a case-only analysis, comparing the effect sizes in the subtypes by 
estrogen receptor status.  For iCHAVs 2a and 2b, only SNPs with P-cond<1x10-4 for overall breast cancer risk are shown here - full results are 
listed in Table S5 and all other iCHAV2a and 2b candidate variants are listed in Table S7. 
aThe best candidate SNP in the iCHAV. 
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Table 2. Breast cancer risk in Europeans by haplotypes of five iCHAV representative SNPs  
       Overall Breast cancer ER+  Breast cancer ER-  Breast cancer 
Haplotype iCHAV1
a 
iCHAV2a
b 
iCHAV2b
c 
iCHAV2c
d 
iCHAV3
e 
Frequency OR (95%CI) P-value OR (95%CI) P-value OR (95%CI) P-value 
h0
f 
1 1 1 1 1 0.52 - - - - - - - - - 
h1 1 1 1 2 1 0.12 1.01 (0.99-1.05) 4.50E-01 1.03 (0.99-1.07) 1.12E-01 1.04 (0.98-1.11) 2.08E-01 
h2 1 1 1 1 2 0.15 0.95 (0.92-0.97) 2.08E-04 0.95 (0.92-0.99) 5.23E-03 1.04 (0.98-1.10) 1.67E-01 
h3 1 2 1 1 1 0.02 1.08 (0.99-1.17) 7.57E-02 1.13 (1.02-1.24) 1.68E-02 1.08 (0.92-1.27) 3.45E-01 
h4 1 2 1 2 1 0.01 1.05 (0.99-1.17) 3.81E-01 0.99 (0.87-1.13) 8.75E-01 1.17 (0.96-1.42) 1.12E-01 
h5 2 1 2 1 1 0.11 1.16 (1.12-1.20) 2.00E-20 1.19 (1.14-1.23) 9.37E-20 1.10 (1.04-1.18) 1.82E-03 
h6 2 2 1 2 1 0.05 1.31 (1.25-1.37) 1.66E-29 1.34 (1.27-1.42) 3.74E-27 1.15 (1.05-1.25) 3.64E-03 
 
a
 rs62355902, representing 15 SNPs 
b
 rs113317823,representing 90 SNPs which have r
2
≥0.53 with rs113317823 and r
2
 in [0.19-0.29] with rs62355902 
c
 rs62355899, representing 66 SNPs which have r
2
≤0.01 with rs113317823 and r
2
 in [0.59-0.62] with rs62355902 
d
 rs7721581, representing 17 SNPs which have r
2
 in [0.14-0.16] with rs113317823 and r
2
≤0.01 with rs62355902 
e
 rs11949391, representing 5 SNPs 
f
h1-h6 are compared to h0 (the reference haplotype carrying the major alleles of all 5 SNPs). 
‘1’ represents major alleles and ‘2’ minor alleles in each SNP 
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